Pharm'Up 
Glenmark Pharmaceuticals, through its subsidiary Glenmark Specialty SA, has received final approval from the U.S. Food and Drug Administration (FDA) for its Fluticasone Propionate Inhalation Aerosol USP (44 mcg per actuation). This product serves as a generic equivalent to Flovent HFA, a widely prescribed inhaled corticosteroid for the long-term management of asthma.
Key Highlights of the Approval
- Therapeutic Equivalence: The FDA has determined that Glenmark’s inhaler is bioequivalent and therapeutically equivalent to the reference branded drug, ensuring it provides the same clinical benefits.
- Market Exclusivity: Glenmark was granted the Competitive Generic Therapy (CGT) designation. As the first approved applicant for this generic, the company is entitled to 180 days of market exclusivity upon its U.S. launch.
- Launch Timeline: Distribution in the United States is scheduled to begin in March 2026 via Glenmark’s American subsidiary.
Market Impact and Demand
The approval addresses a high-demand sector of the respiratory market. According to IQVIA data for the 12-month period ending January 2026, the U.S. market for the 44 mcg strength of Flovent HFA generated approximately $520 million in annual sales. This generic entry is expected to enhance patient access to more affordable asthma maintenance options.
Clinical Use
Fluticasone propionate is an inhaled corticosteroid designed to reduce inflammation in the lungs.
- Indication: It is used for the maintenance treatment of asthma to prevent symptoms like wheezing and shortness of breath.
- Important Limitation: This medication is for regular, long-term control and is not intended for immediate relief during an acute or sudden asthma attack.
About the Author
